Clinical Exome Sequencing Study in a Cohort of Growth Hormone-Secreting Pituitary Adenomas.

What Was Tested

This observational study looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Therefore, this study aimed to investigate germline genetic variants in patients with acromegaly through clinical exome sequencing (CES) analysis and to explore a possible correlation with the molecular and histological characteristics of somatotropinomas and the clinical features of acromegaly.

A retrospective observational study was conducted to investigate the genetic profile of 46 patients with sporadic acromegaly through CES analysis, in comparison with 39 controls.

Why It Was Studied

Genetic mutations have been reported in patients with acromegaly, potentially influencing clinical phenotype, tumor invasiveness, and prognosis.

The genetic and molecular landscape of patients with acromegaly has been partially explored.

Who Took Part

The study group was 46 patients.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

What Was Measured

Topics PubMed links to this paper include Growth Hormone-Secreting Pituitary Adenoma, Exome Sequencing, Adenoma, Acromegaly, Cohort Studies, Genetic Predisposition to Disease and Germ-Line Mutation.

Author keywords: clinical exome sequencing, genetics, germline mutations, pituitary adenomas and sporadic tumors.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 46 patients.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Endocrine, metabolic & immune disorders drug targets), a journal based in United Arab Emirates.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.